Kymera Therapeutics annual operating income
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Operating Income Growth & History (KYMR)
Kymera Therapeutics's operating income was −$349.4M for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$349.4M | −$87.8M | — |
| 2024 | 2024-12-31 | −$261.6M | −$96.1M | — |
| 2023 | 2023-12-31 | −$165.5M | −$4.3M | — |
| 2022 | 2022-12-31 | −$161.3M | −$60.7M | — |
| 2021 | 2021-12-31 | −$100.5M | −$54.2M | — |
| 2020 | 2020-12-31 | −$46.3M | −$4.1M | — |
| 2019 | 2019-12-31 | −$42.2M | — | — |
Kymera Therapeutics quarterly operating income
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$75.6M | $8.9M | — |
| Q1 2026 | 2026-03-31 | −$84.2M | −$9.7M | — |
| Q4 2025 | 2025-12-31 | −$97.9M | −$17.1M | — |
| Q3 2025 | 2025-09-30 | −$92.5M | −$20.4M | — |
| Q2 2025 | 2025-06-30 | −$84.6M | −$33.6M | — |
| Q1 2025 | 2025-03-31 | −$74.4M | −$16.6M | — |
| Q4 2024 | 2024-12-31 | −$80.8M | −$61.4M | — |
| Q3 2024 | 2024-09-30 | −$72.1M | −$14.6M | — |
| Q2 2024 | 2024-06-30 | −$50.9M | −$7.5M | — |
| Q1 2024 | 2024-03-31 | −$57.8M | −$12.5M | — |
| Q4 2023 | 2023-12-31 | −$19.3M | $19.3M | — |
| Q3 2023 | 2023-09-30 | −$57.5M | −$12.6M | — |
| Q2 2023 | 2023-06-30 | −$43.4M | −$2.6M | — |
| Q1 2023 | 2023-03-31 | −$45.3M | −$8.4M | — |
| Q4 2022 | 2022-12-31 | −$38.6M | −$4.6M | — |
| Q3 2022 | 2022-09-30 | −$44.9M | −$16.2M | — |
| Q2 2022 | 2022-06-30 | −$40.8M | −$16.1M | — |
| Q1 2022 | 2022-03-31 | −$36.9M | −$23.8M | — |
| Q4 2021 | 2021-12-31 | −$34.0M | −$21.2M | — |
| Q3 2021 | 2021-09-30 | −$28.6M | −$20.6M | — |
| Q2 2021 | 2021-06-30 | −$24.7M | −$10.5M | — |
| Q1 2021 | 2021-03-31 | −$13.2M | −$1.9M | — |
| Q4 2020 | 2020-12-31 | −$12.8M | — | — |
| Q3 2020 | 2020-09-30 | −$8.1M | $3.8M | — |
| Q2 2020 | 2020-06-30 | −$14.2M | — | — |
| Q1 2020 | 2020-03-31 | −$11.2M | — | — |
| Q3 2019 | 2019-09-30 | −$11.9M | — | — |
Kymera Therapeutics operating income trends
Over the last five fiscal years, Kymera Therapeutics's operating income decreased from −$46.3M to −$349.4M, a change of −$303.1M. The latest reported quarter, Q2 2026, shows −$75.6M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗Community posts
Kymera reports early human results for oral IRF5 drug
Kymera ($KYMR) reported results from its first human study of KT-579, an experimental oral medicine targeting the immune regulator IRF5. In healthy volunteers receiving repeated doses, median blood IRF5 reductions reached at least 90% acros ...
